Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.5M rose 1.5% year over year, ahead of the -11.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.

Context

  • Stock-based compensation amounted to 2.4% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.5% holds above the trailing-twelve-month pace of -11.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.5M+4.8% QoQ
Last fiscal yearDec 2025
$9.87M-17.7% YoY
LTMMar 2026
$9.91M-11.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year-17.7%——
3-year CAGR-13.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.87M USD
Year-over-year change
-17.7%
4-year CAGR
-20.2%

Stock-Based Compensation vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.7% is the 8th highest of 10, against a peer median of +3.6%.
  • Stock-based compensation amounts to 2.4% of revenue for ESPR, versus a peer median of 5.1%.
ESPR Competitors
Stock-Based Compensation for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OFIXOrthofix Medical Inc.LTM Mar 2026$42.3M USD+40.4%+15.9%5.1%
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M USD-7.4%-5.4%39.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$16.6M USD+22.1%-28.9%2.5%
ABSIAbsci CorporationLTM Mar 2026$13.53M USD-11.4%+13.5%737.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M USD-40.1%——
SNDLSNDL Inc.LTM Mar 2026CA$13.13M CAD-20.8%+12.9%1.4%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$9.91M USD-11.7%-13.4%2.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$8.36M USD+17.6%+20.3%16.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M USD+88.8%+25.6%—
SIGASIGA Technologies, Inc.LTM Mar 2026$3.53M USD+3.6%+27.4%3.8%
Peer median (excluding ESPR) —+3.6%+14.7%5.1%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Depreciation & Amortization612K500K164K63K105K
Deferred Income Tax00000
Stock-Based Compensation24.31M15.22M11.96M11.99M9.87M
Change in Working Capital(52.51M)(3.37M)13.68M(60.53M)(14.64M)
Accounts Receivables(10.55M)(10.8M)(14.77M)(31.65M)(60.05M)
Inventory(18.26M)(807K)(30.42M)(28.87M)(10.63M)
Accounts Payables(34.1M)5.6M8.68M12.43M20.92M
Other Working Capital10.39M2.63M50.18M(12.45M)35.12M
Other Non-Cash Items32.89M46.49M47.96M76.57M14.26M
Operating Cash Flow(263.81M)(174.83M)(135.49M)(23.65M)(13.09M)
Capital Expenditures000(317K)0
Acquisitions (Net)00000
Purchases of Investments(50.48M)(59.9M)000
Sales of Investments068M42.5M00
Other Investing Activities00000
Investing Cash Flow(50.48M)8.1M42.5M(317K)0
Debt Repayment(440K)(58.24M)(15.51M)35.01M(54.91M)
Common Stock Issued218.69M90.85M56.88M91.19M98.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities49.98M0(6.42M)(39.72M)(7.26M)
Financing Cash Flow268.22M32.61M50.46M86.48M36.18M
Effect of Forex Changes00000
Net Change in Cash(46.07M)(134.12M)(42.53M)62.51M23.09M
Free Cash Flow(263.81M)(174.83M)(135.49M)(23.97M)(13.09M)

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.